Agenus (NASDAQ: AGEN) and Proteostasis Therapeutics (NASDAQ:PTI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, analyst recommendations, risk, profitability, dividends and earnings.
Valuation and Earnings
This table compares Agenus and Proteostasis Therapeutics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Agenus||$42.88 million||13.47||-$120.69 million||($1.22)||-4.61|
|Proteostasis Therapeutics||$5.34 million||33.32||-$59.43 million||($2.35)||-2.20|
Proteostasis Therapeutics has lower revenue, but higher earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Proteostasis Therapeutics, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and recommmendations for Agenus and Proteostasis Therapeutics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Agenus presently has a consensus price target of $6.33, indicating a potential upside of 12.49%. Proteostasis Therapeutics has a consensus price target of $14.75, indicating a potential upside of 185.85%. Given Proteostasis Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Proteostasis Therapeutics is more favorable than Agenus.
This table compares Agenus and Proteostasis Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Agenus has a beta of 1.5, suggesting that its stock price is 50% more volatile than the S&P 500. Comparatively, Proteostasis Therapeutics has a beta of 6.66, suggesting that its stock price is 566% more volatile than the S&P 500.
Insider & Institutional Ownership
36.7% of Agenus shares are owned by institutional investors. Comparatively, 70.5% of Proteostasis Therapeutics shares are owned by institutional investors. 7.9% of Agenus shares are owned by insiders. Comparatively, 17.4% of Proteostasis Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Proteostasis Therapeutics beats Agenus on 9 of the 14 factors compared between the two stocks.
Agenus Company Profile
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company’s discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company’s vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Proteostasis Therapeutics Company Profile
Proteostasis Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models. Using this platform, it has identified a new class of small molecules, amplifiers that modulate proteins in the proteostasis network. It is developing and intend to commercialize its lead amplifier of CFTR protein, PTI-428, to improve CFTR protein function. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program. PTI-130 is a small molecule amplifier.
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.